



Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Leap Presentation Details:

Piper Sandler 35th Annual Healthcare Conference

Date: Tuesday, November 28, 2023

Time: 8:00 a.m. Eastern Time

A live webcast of the fireside chat may be accessed on the Investors page of the company's website at <https://investors.leaptx.com/>, where a replay of the events will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, visit <http://www.leaptx.com> or view our public filings with the SEC that are available via EDGAR at <http://www.sec.gov> or via <https://investors.leaptx.com/>.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com



View original content to download multimedia:<https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-35th-annual-healthcare-conference-301991880.html>

SOURCE Leap Therapeutics, Inc.